# US 2003/0215846 A1 · Methods of constructing and screening diverse expression libraries

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215846 A1
- Document ID: US20030215846A1
- Status: Published application
- Kind: A1
- Application number: 10/372,003
- Filed: 2003-02-21
- Published: 2003-11-20
- Earliest claimed: 1999-05-05
- Assignees: Phylogica Limited
- Inventors: Paul M. Watt; Wayne Thomas; Richard Hopkins
- Web page: https://patentgrep.com/patent/US20030215846A1

## CPC

- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/001: {by chemical synthesis}
- C12N 15/1034: {Isolating an individual clone by screening libraries}
- C12N 15/1086: {Preparation or screening of expression libraries, e.g. reporter assays}
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/575: for cancer
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid fragments of the libraries are derived from two or more diverse characterized genomes.

## Claims

### Claim 1

A method of constructing an expression library for expressing a peptide having a conformation sufficient for binding to a target protein or nucleic acid, said method comprising:
(c) producing nucleic acid fragments from nucleic acids derived from two or more microorganisms or eukaryotes containing compact genomes, each of said microorganisms or eukaryotes having a substantially sequenced genome; and
(d) inserting the nucleic acid fragments at (a) into a suitable expression construct thereby producing recombinant constructs, wherein each fragment is in operable connection with a promoter sequence that is capable of conferring expression of that fragment.

### Claim 2 (depends on 1)

The method of claim 1 wherein the fragments at (a) are inserted into a suitable expression vector in an amount proportional to the size of the genome from which the fragments were derived.

### Claim 3 (depends on 1)

The method of claim 1 further comprising selecting those nucleic acid fragments from the fragments at (a) that encode a peptide having an average length of at least about 12-15 amino acid residues and/or encode a protein domain; and

### Claim 4 (depends on 1)

The method of claim 1 further comprising selecting nucleic acid fragments from the fragments at (a) that have substantially different nucleotide sequences thereby enhancing nucleotide sequence diversity among the selected fragments compared to the diversity of sequences in the genome.

### Claim 5 (depends on 4)

The method of claim 4 wherein the selection comprises subjecting a base nucleic acid fragment to mutagenesis to produce a mutated fragment and optionally combining the mutated fragment with the base nucleic acid fragment.

### Claim 6 (depends on 4)

The method of claim 4 wherein the selection comprises mutating a nucleic acid fragment thereby permitting the nucleic acid fragment to be read in any one or more of three forward reading frames.

### Claim 7 (depends on 6)

The method of claim 6 wherein one or more nucleotide residues are added to the 5′-end or 3′-end of a nucleic acid fragment.

### Claim 8 (depends on 6)

The method of claim 6 wherein one or more nucleotides is inserted into an internal region of a nucleic acid fragment.

### Claim 9 (depends on 6)

The method of claim 6 wherein one or more nucleotides is deleted from the nucleic acid fragment.

### Claim 10 (depends on 6)

The method of claim 6 wherein one or more nucleotides of the nucleic acid fragment is substituted for another nucleotide residue.

### Claim 11 (depends on 4)

The method of claim 4 wherein the selection comprises positioning a first codon of the nucleic acid fragment at different locations relative to the translation start site such that each three forward reading frame is used.

### Claim 12 (depends on 4)

The method of claim 4 wherein the selection comprises cloning a nucleic acid fragment in a reverse orientation relative to the orientation of the fragment in the context of the gene from which it was derived.

### Claim 13 (depends on 4)

The method of claim 4 wherein the selection comprises deleting a nucleic acid fragment having a redundant nucleotide sequence.

### Claim 14

A method of constructing an expression library for expressing a polypeptide having a conformation sufficient for binding to a target protein or nucleic acid, said method comprising:
(a) producing nucleic acid fragments from nucleic acids derived from two or more microorganisms or eukaryotes containing compact genomes, each of said microorganisms or eukaryotes having a substantially sequenced genome;
(b) selecting nucleic acid fragments from the fragments at (a) that have substantially different nucleotide sequences thereby enhancing nucleotide sequence diversity among the selected fragments compared to the diversity of sequences in the genome and selecting nucleic acid fragments from the fragments at (a) that encode a peptide having an average length of at least about 12-15 amino acid residues and/or encode a protein domain; and
(c) inserting the selected fragments at (a) into a suitable expression vector in an amount proportional to the size of the genome from which the fragments were derived thereby producing recombinant constructs, wherein each fragment is in operable connection with a promoter sequence that is capable of conferring expression of that fragment.

### Claim 15

A method of constructing an expression library for expressing a polypeptide having a conformation sufficient for binding to a target protein or nucleic acid, said method comprising:
(a) producing nucleic acid fragments from nucleic acids derived from one microorganism or eukaryote containing a compact genome, wherein the genome of the microorganism or eukaryote is a substantially sequenced genome;
(b) selecting nucleic acid fragments from the fragments at (a) that encode a peptide having an average length of at least about 12-15 amino acid residues and/or encode a protein domain; and
(c) inserting the selected fragments at (b) into a suitable expression vector thereby producing recombinant constructs, wherein each fragment is in operable connection with a promoter sequence that is capable of conferring expression of that fragment.

### Claim 16

A method of constructing an expression library for expressing a polypeptide having a conformation sufficient for binding to a target protein or nucleic acid, said method comprising:
(a) producing nucleic acid fragments from nucleic acids derived from one microorganism or eukaryote containing a compact genome, wherein the genome of the microorganism or eukaryote is a substantially sequenced genome;
(b) selecting nucleic acid fragments from the fragments at (a) that have substantially different nucleotide sequences thereby enhancing nucleotide sequence diversity among the selected fragments compared to the diversity of sequences in the genome; and
(c) selecting nucleic acid fragments from the fragments at (a) that encode a peptide having an average length of at least about 12-15 amino acid residues and/or encode a protein domain; and
(d) inserting the selected fragments at (b) into a suitable expression vector thereby producing recombinant constructs, wherein each fragment is in operable connection with a promoter sequence that is capable of conferring expression of that fragment.

### Claim 17 (depends on 16)

The method of claim 16 wherein the selection at (b) comprises subjecting a base nucleic acid fragment to mutagenesis to produce a mutated fragment and optionally combining the mutated fragment with the base nucleic acid fragment.

### Claim 18 (depends on 16)

The method of claim 16 wherein the selection at (b) comprises mutating a nucleic acid fragment thereby permitting the nucleic acid fragment to be read in any one or more of three forward reading frames.

### Claim 19 (depends on 18)

The method of claim 18 wherein one or more nucleotide residues are added to the 5′-end or 3′-end of a nucleic acid fragment.

### Claim 20 (depends on 18)

The method of claim 18 wherein one or more nucleotides is inserted into an internal region of a nucleic acid fragment.

### Claim 21 (depends on 18)

The method of claim 18 wherein one or more nucleotides is deleted from the nucleic acid fragment.

### Claim 22 (depends on 18)

The method of claim 18 wherein one or more nucleotides of the nucleic acid fragment is substituted for another nucleotide residue.

### Claim 23 (depends on 19)

The method of claim 19 comprising positioning a first codon of the nucleic acid fragment at different locations relative to the translation start site such that each three forward reading frame is used.

### Claim 24 (depends on 16)

The method of claim 16 wherein the selection at (b) comprises cloning a nucleic acid fragment in a reverse orientation relative to the orientation of the fragment in the context of the gene from which it was derived.

### Claim 25 (depends on 16)

The method of claim 16 wherein the selection at (b) comprises deleting a nucleic acid fragment having a redundant nucleotide sequence.

### Claim 26

A method of constructing an expression library for expressing a polypeptide having a conformation sufficient for binding to a target protein or nucleic acid, said method comprising:
(a) producing nucleic acid fragments from nucleic acids derived from one microorganism or eukaryote containing a compact genome, wherein the genome of the microorganism or eukaryote is a substantially sequenced genome;
(b) selecting nucleic acid fragments from the fragments at (a) that have substantially different nucleotide sequences thereby enhancing nucleotide sequence diversity among the selected fragments compared to the diversity of sequences in the genome and selecting nucleic acid fragments from the fragments at (a) that encode a peptide having an average length of at least about 12-15 amino acid residues and/or encode a protein domain; and
(c) inserting the selected fragments at (b) into a suitable expression construct thereby producing recombinant constructs, wherein each fragment is in operable connection with a promoter sequence that is capable of conferring expression of that fragment.

### Claim 27 (depends on 1)

The method of claim 1, further comprising introducing the recombinant construct into a host cell.

### Claim 28 (depends on 14)

The method of claim 14, further comprising introducing the recombinant construct into a host cell.

### Claim 29 (depends on 15)

The method of claim 15, further comprising introducing the recombinant construct into a host cell.

### Claim 30 (depends on 16)

The method of claim 16, further comprising introducing the recombinant construct into a host cell.

### Claim 31 (depends on 26)

The method of claim 26, further comprising introducing the recombinant construct into a host cell.

### Claim 32 (depends on 1)

An expression library produced by the method of claim 1.

### Claim 33 (depends on 14)

An expression library produced by the method of claim 14.

### Claim 34 (depends on 15)

An expression library produced by the method of claim 15.

### Claim 35 (depends on 16)

An expression library produced by the method of claim 16.

### Claim 36 (depends on 26)

An expression library produced by the method of claim 26.

### Claim 37

An expression library comprising nucleic acid fragments derived from one or more microorganisms or eukaryotes containing compact genomes, each of said microorganisms or eukaryotes having a substantially sequenced genome, wherein the nucleic acid fragments of the library comprise an open reading frame having an average length of at least about 36-45 nucleotide residues and/or encode a protein domain, and wherein the nucleic acid fragments are inserted into an expression vector thereby producing recombinant constructs wherein each fragment is in operable connection with a promoter sequence that is capable of conferring expression of that fragment.

### Claim 38

An expression library comprising nucleic acid fragments derived from one or more microorganisms or eukaryotes containing compact genomes, each of said microorganisms or eukaryotes having a substantially sequenced genome, wherein the nucleic acid fragments of the library have substantially different nucleotide sequences and wherein the nucleic acid fragments are inserted into an expression vector thereby producing recombinant constructs wherein each fragment is in operable connection with a promoter sequence that is capable of conferring expression of that fragment.

### Claim 39 (depends on 37)

The expression library of claim 37 wherein the nucleic acid fragments are derived from an organism selected from the group consisting of: Aeropyrum pernix, Anopheles gambiae, Arabidopsis thaliana, Aquifex aeolicus, Archaeoglobus fulgidis, Bacillus subtilis, Bordetella pertussis, Borrelia burgdorferi, Caenorhabditis elegans, Chlamydia trachomatis, Danio rerio, Drosophila melanogaster, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Methanobacterium thermoautotrophicum, Methanococcus jannaschii, Mycoplasma pneumoniae, Neisseria meningitidis, Pseudomonas aeruginosa, Pyrococcus horikoshii, Saccharomyces cerevesiae, Schizosaccharomyces pombe, Synechocystis PCC 6803, Takifugu rubripes, Thermoplasma volcanium, and Thermotoga maritima;

### Claim 40 (depends on 38)

The expression library of claim 38 wherein the nucleic acid fragments are derived from an organism selected from the group consisting of: Aeropyrum pernix, Anopheles gambiae, Arabidopsis thaliana, Aquifex aeolicus, Archaeoglobus fulgidis, Bacillus subtilis, Bordetella pertussis, Borrelia burgdorferi, Caenorhabditis elegans, Chlamydia trachomatis, Danio rerio, Drosophila melanogaster, Escherichia coli, Haemophilus influenzae, Helicobacter pylori, Methanobacterium thermoautotrophicum, Methanococcus jannaschii, Mycoplasma pneumoniae, Neisseria meningitidis, Pseudomonas aeruginosa, Pyrococcus horikoshii, Saccharomyces cerevesiae, Schizosaccharomyces pombe, Synechocystis PCC 6803, Takifugu rubripes, Thermoplasma volcanium, and Thermotoga maritima;

### Claim 41 (depends on 37)

The expression library of claim 37 wherein the expression vector is a plasmid, bacteriophage or phagemid.

### Claim 42 (depends on 41)

The expression library of claim 41 wherein the expression vector comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 60 and SEQ ID NO: 61.

### Claim 43 (depends on 38)

The expression library of claim 38 wherein the expression vector is a plasmid, bacteriophage or phagemid.

### Claim 44 (depends on 43)

The expression library of claim 43 wherein the expression vector comprises the nucleotide sequence selected from the group consisting of SEQ ID NO: 36, SEQ ID NO: 60 and SEQ ID NO: 61.

### Claim 45 (depends on 37, 38)

The expression library of claim 37 or 38 wherein the number of genomes of a microorganism or eukaryote that is represented in the library is more than one.

### Claim 46 (depends on 45)

The expression library of claim 45 wherein the nucleic acid fragments are represented in an amount proportional to the size of the genome of a microorganism or eukaryote from which the fragments were derived.

### Claim 47 (depends on 37, 38)

The expression library of claim 37 or 38 wherein the recombinant vector is in a cellular host.

### Claim 48 (depends on 47)

The expression library of claim 47 wherein the cellular host is a bacterium.

### Claim 49 (depends on 47)

The expression library of claim 47 wherein the cellular host is a yeast.

### Claim 50 (depends on 47)

The expression library of claim 47 wherein the cellular host is a nematode.

### Claim 51 (depends on 50)

The expression library of claim 50 wherein the nematode is C. elegans.

### Claim 52 (depends on 37)

A method of determining a peptide that binds to a target nucleic acid or target protein comprising:
(a) screening the expression library of claim 37 to identify a peptide expressed by the library that binds to a target protein or target nucleic acid; and
(b) selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment.

### Claim 53 (depends on 52)

The method of claim 52 further comprising obtaining the expression library.

### Claim 54 (depends on 52)

The method of claim 52 further comprising producing the expression library.

### Claim 55 (depends on 52)

The method of claim 52 wherein screening the library comprises performing an assay selected from the group consisting of yeast-2-hybrid, n-hybrid, reverse-2-hybrid, reverse n-hybrid, split two hybrid, bacterial display, phage display, retroviral display, covalent display and in vitro display.

### Claim 56 (depends on 52)

The method of claim 52 wherein screening the library comprises an affinity purification.

### Claim 57 (depends on 56)

The method of claim 56 wherein the affinity purification comprises the formation of an antigen-antibody complex.

### Claim 58 (depends on 52)

The method of claim 52 wherein selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment comprises:
(i) determining the amino acid sequence of the peptide or determining the nucleotide sequence of the corresponding nucleic acid encoding said peptide and deriving the amino acid sequence from said nucleotide sequence;
(ii) determining a known function of the amino acid sequence; and
(iii) excluding a peptide that binds to a target protein or target nucleic acid associated with the known function.

### Claim 59 (depends on 52)

The method of claim 52 wherein selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment comprises using an expression library that comprises nucleic acid fragments from organisms that do not possess a biochemical pathway or signal transduction pathway relevant to the binding reaction being assayed at (a).

### Claim 60 (depends on 52)

The method of claim 52 wherein selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment comprises using an expression library that comprises nucleic acid fragments from organisms that do not express one or more of the binding partners of the binding reaction being assayed.

### Claim 61 (depends on 52)

The method of claim 52 further comprising recovering a peptide that binds to the target protein or nucleic acid or nucleic acid encoding said peptide.

### Claim 62 (depends on 38)

A method of determining a peptide that binds to a target nucleic acid or target protein comprising:
(a) screening the expression library of claim 38 to identify a peptide expressed by the library that binds to a target protein or target nucleic acid; and
(b) selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment.

### Claim 63 (depends on 62)

The method of claim 62 further comprising obtaining the expression library.

### Claim 64 (depends on 62)

The method of claim 62 further comprising producing the expression library.

### Claim 65 (depends on 62)

The method of claim 62 wherein screening the library comprises performing an assay selected from the group consisting of yeast-2-hybrid, n-hybrid, reverse-2-hybrid, reverse n-hybrid, split two hybrid, bacterial display, phage display, retroviral display, covalent display and in vitro display.

### Claim 66 (depends on 62)

The method of claim 62 wherein screening the library comprises an affinity purification.

### Claim 67 (depends on 66)

The method of claim 66 wherein the affinity purification comprises the formation of an antigen-antibody complex.

### Claim 68 (depends on 62)

The method of claim 62 wherein selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment comprises:
(i) determining the amino acid sequence of the peptide or determining the nucleotide sequence of the corresponding nucleic acid encoding said peptide and deriving the amino acid sequence from said nucleotide sequence;
(ii) determining a known function of the amino acid sequence; and
(iii) excluding a peptide that binds to a target protein or target nucleic acid associated with the known function.

### Claim 69 (depends on 62)

The method of claim 62 wherein selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment comprises using an expression library that comprises nucleic acid fragments from organisms that do not possess a biochemical pathway or signal transduction pathway relevant to the binding reaction being assayed at (a).

### Claim 70 (depends on 62)

The method of claim 62 wherein selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment comprises using an expression library that comprises nucleic acid fragments from organisms that do not express one or more of the binding partners of the binding reaction being assayed.

### Claim 71 (depends on 62)

The method of claim 62 further comprising recovering a peptide that binds to the target protein or nucleic acid or nucleic acid encoding said peptide.

### Claim 72

An isolated peptide or protein domain that binds to an immunoglobulin, wherein said immunoglobulin was not raised against the peptide or protein domain and wherein said peptide or protein domain does not have a native function of the protein against which the immunoglobulin was prepared.

### Claim 73 (depends on 72)

The isolated peptide or protein domain of claim 72 wherein the peptide or protein domain binds to antibodies against an allergen.

### Claim 74 (depends on 72)

The isolated peptide or protein domain of claim 72 wherein the allergen is a pollen allergen.

### Claim 75 (depends on 74)

The isolated peptide or protein domain of claim 74 wherein the pollen allergen is a Der p1 protein.

### Claim 76 (depends on 37)

An isolated peptide or protein domain that partially or completely inhibits or antagonizes or blocks an interaction between two or more proteins in a cell isolated by a process comprising performing the method of claim 37.

### Claim 77

An isolated peptide or protein domain that partially or completely inhibits or antagonizes or blocks an interaction between SCL and E47 in a cell.

### Claim 78

An isolated peptide or protein domain that partially or completely inhibits or antagonizes or blocks an interaction between SCL and E47 in a cell said peptide or protein domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 79 and SEQ ID NO: 81.

### Claim 79

An isolated nucleic acid comprising a nucleotide sequence that encodes a peptide or protein domain that partially or completely inhibits or antagonizes or blocks an interaction between SCL and E47 in a cell and comprising a nucleotide sequence selected from the group consisting of: SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 78 and SEQ ID NO: 80.

### Claim 80 (depends on 32)

A database comprising the nucleotide sequences of nucleic acid fragments of the expression library of claim 32 or the amino acid sequences of the peptides encoded by said nucleic acid fragments in computer readable form.

### Claim 81 (depends on 33)

A database comprising the nucleotide sequences of nucleic acid fragments of the expression library of claim 33 or the amino acid sequences of the peptides encoded by said nucleic acid fragments in computer readable form.

### Claim 82 (depends on 34)

A database comprising the nucleotide sequences of nucleic acid fragments of the expression library of claim 34 or the amino acid sequences of the peptides encoded by said nucleic acid fragments in computer readable form.

### Claim 83 (depends on 35)

A database comprising the nucleotide sequences of nucleic acid fragments of the expression library of claim 35 or the amino acid sequences of the peptides encoded by said nucleic acid fragments in computer readable form.

### Claim 84 (depends on 36)

A database comprising the nucleotide sequences of nucleic acid fragments of the expression library of claim 36 or the amino acid sequences of the peptides encoded by said nucleic acid fragments in computer readable form.

### Claim 85 (depends on 37)

A database comprising the nucleotide sequences of nucleic acid fragments of the expression library of claim 37 or the amino acid sequences of the peptides encoded by said nucleic acid fragments in computer readable form.

### Claim 86 (depends on 38)

A database comprising the nucleotide sequences of nucleic acid fragments of the expression library of claim 38 or the amino acid sequences of the peptides encoded by said nucleic acid fragments in computer readable form.

### Claim 87 (depends on 52)

A method for determining or validating a target comprising
(a) performing the method of claim 52 to thereby identify a peptide expressed by the library that binds to a target protein or target nucleic acid;
(b) selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment; and
(c) expressing the selected peptide in an organism and determining a phenotype of the organism that is modulated by the target protein or target nucleic acid.

### Claim 88 (depends on 62)

A method for determining or validating a target comprising
(a) performing the method of claim 62 to thereby identify a peptide expressed by the library that binds to a target protein or target nucleic acid;
(b) selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment; and
(c) expressing the selected peptide in an organism and determining a phenotype of the organism that is modulated by the target protein or target nucleic acid.

### Claim 89 (depends on 52)

A method for identifying a therapeutic or prophylactic compound comprising
(a) performing the method of claim 52 to thereby identify a peptide expressed by the library that binds to a target protein or target nucleic acid;
(b) selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment;
(c) expressing the selected peptide in an organism and determining a phenotype of the organism that is modulated by the target protein or target nucleic acid; and
(d) identifying a mimetic compound of a peptide that modulated the phenotype of the organism.

### Claim 90 (depends on 62)

A method for identifying a therapeutic or prophylactic compound comprising
(a) performing the method of claim 62 to thereby identify a peptide expressed by the library that binds to a target protein or target nucleic acid;
(b) selecting a peptide from (a) that does not bind to said target protein or nucleic acid in its native environment;
(c) expressing the selected peptide in an organism and determining a phenotype of the organism that is modulated by the target protein or target nucleic acid; and
(d) identifying a mimetic compound of a peptide that modulated the phenotype of the organism.
